MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise

McKesson Corporation MCK used its first-quarter fiscal 2027 call to frame the year around stronger North American Pharmaceutical execution, specialty demand and disciplined reinvestment. Management raised full-year adjusted earnings guidance after the segment delivered 19% operating profit growth.

Adjusted earnings of $9.93 per share exceeded the Zacks Consensus Estimate of $9.44, while revenues of $105.38 billion topped the $104.39 billion estimate. The call centered on the durability and timing of those gains.

McKesson Corporation Price, Consensus and EPS Surprise

McKesson Corporation price-consensus-eps-surprise-chart | McKesson Corporation Quote

MCK Raises Full-Year Outlook

Chief financial officer Kenny Cheung said first-quarter performance exceeded management’s expectations and supported raising fiscal 2027 adjusted earnings guidance to $44.20-$45.00 from $43.80-$44.60.

Cheung said most of the increase came from North American Pharmaceutical, with operating profit growth now expected at the high end of the prior 5.5%-9.5% range.

During the Wells Fargo Q&A, CFO Cheung described the outlook as a balanced view rather than a best-case scenario. He also noted that June was the quarter’s strongest month.

McKesson Leans on Pharma Strength

CFO Kenny Cheung attributed the segment’s 5% revenue growth to higher prescription volumes, including specialty products. Adjusted operating profit rose 19% on specialty distribution growth and new-product launch timing.

A Deutsche Bank analyst asked whether margin expansion reflected one-time factors. CFO Cheung said mix across customers, products and channels can move margins, while lower branded drug prices had little operating profit impact.

A Leerink Partners analyst pressed on the back-half cadence. Chairman and CEO Brian Tyler said some generic favorability arrived earlier than expected, while Cheung said second-half spending will accelerate around growth and artificial intelligence.

MCK Expands Oncology Platform

CEO Tyler emphasized McKesson’s reach across more than 14,000 community-based specialty providers, including approximately 3,400 providers in The U.S. Oncology Network.

Cheung said Oncology & Multispecialty revenues rose 33%, or approximately 24%, excluding Core Ventures. Adjusted operating profit grew 41%, supported by provider solutions and specialty distribution.

An Evercore ISI analyst asked about Florida Cancer Specialists. CEO Tyler said integration, operations and financial performance were at the high end of acquisition expectations. In response to Nephron Research, he highlighted physician recruitment, geographic expansion and technology-enabled capacity as growth drivers.

McKesson Advances Wellverse Separation

Tyler said Medical-Surgical Solutions will begin operating as Wellverse in January 2027. McKesson sold Apollo Funds an approximately 13% minority stake for $1.25 billion and established a $2.25 billion secured Term Loan B facility.

The segment’s revenues rose 4%, but adjusted operating profit fell 20% because of product mix and one-time administrative expenses, partly offset by extended-care contributions.

Cheung said separation financing is reflected in fiscal 2027 interest expense guidance of $380 million-$420 million. McKesson also expects approximately $5 billion of share repurchases, with $2.5 billion completed in the first quarter.

MCK Addresses Policy and Cash Flow

A JPMorgan analyst asked about 340B reform and drug-pricing policy. Tyler said the 340B proposal remained under review and that estimating a financial impact would be premature.

Tyler added McKesson’s scale, technology, compliance capabilities and customer relationships should help stakeholders navigate policy changes. Cheung said that wholesale acquisition cost movements affect revenues more than gross profit or operating profit.

A UBS analyst questioned the gap between earnings and free cash flow. Cheung said the $372 million first-quarter outflow improved from $1.107 billion a year earlier, while technology and AI were driving structural working-capital improvements. He maintained the $4.5 billion-$4.9 billion full-year outlook.

McKesson Keeps Focus on Execution

Tyler kept the emphasis on stable utilization, specialty growth, community-based care and technology investments across distribution and biopharma services.

On his first earnings call as CFO, Cheung stressed operating discipline, capital allocation and execution. Management also acknowledged quarter-to-quarter variability from launch timing, investments and comparison effects.

MCK’s Zacks Signals Remain Favorable

MCK currently carries a Zacks Rank #2 (Buy), along with a Value Score of A, Growth Score of B, Momentum Score of C and VGM Score of A. The Style Score framework views A and B grades as favorable complements to a top Zacks Rank. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Momentum Score of C is less supportive than the other style measures. The Zacks Rank can change as earnings estimates are revised following the newly reported results, so the current signal is not permanent.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research